Gout is the most common type of inflammatory disease which is characterized by the accumulation of Monosodium uric acid crystals in joints and tissues thereby leading to recurrent flares of severe joint damage and musculoskeletal disability. Gout is also known as “the disease of kings” or Richman’s disease. Approximately 8 million People in the United States are affected with gout. Worldwide incidence of gout is increasing gradually due to poor dietary habits including fast foods, lack of exercises, increased incidence of obesity and metabolic syndrome. Controlling the acute flares is still a challenging issue in the management of gout. Conventional therapy to treat acute flares have certain limitations, especially with gout patients who frequently have multiple comorbidities such as cardiovascular disease, diabetes mellitus, hypertension, chronic kidney disease and metabolic syndrome. Over the last decade, the better understanding of pathophysiology of gout led to the discovery of new drugs to treat and prevent gout flares and underlying hyperuricemia. In this review, we will focus on various novel drugs for the gout attacks and their safety and efficacy when compared to other conventional drugs used for gout.
Gout, Hyperuricemia, Monosodium Uric acid crystals, Inflammatory arthritis, Richman’s disease